The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes
Open accessAbstract
BACKGROUND: Hybrid closed-loop insulin therapy has shown promise for management of type 1 diabetes during pregnancy; however, its efficacy is unclear. METHODS: In this multicenter, controlled trial, we randomly assigned pregnant women with type 1 diabetes and a glycated hemoglobin level of at least 6.5% at nine sites in the United Kingdom to receive standard insulin therapy or hybrid closed-loop therapy, with both groups using continuous glucose monitoring. The primary outcome was the percentage of time in the pregnancy-specific target glucose range (63 to 140 mg per deciliter [3.5 to 7.8 mmol per liter]) as measured by continuous glucose monitoring from 16 weeks' gestation until delivery. Analyses were performed according to the intention-to-treat principle. Key secondary outcomes were the percentage of time spent in a hyperglycemic state (glucose level >140 mg per deciliter), overnight time in the target range, the glycated hemoglobin level, and safety events. RESULTS: A total of 124 participants with a mean (±SD) age of 31.1±5.3 years and a mean baseline glycated hemoglobin level of 7.7±1.2% underwent randomization. The mean percentage of time that the maternal glucose level was in the target range was 68.2±10.5% in the closed-loop group and 55.6±12.5% in the standard-care group (mean adjusted difference, 10.5 percentage points; 95% confidence interval [CI], 7.0 to 14.0; P<0.001). Results for the secondary outcomes were consistent with those of the primary outcome; participants in the closed-loop group spent less time in a hyperglycemic state than those in the standard-care group (difference, -10.2 percentage points; 95% CI, -13.8 to -6.6); had more overnight time in the target range (difference, 12.3 percentage points; 95% CI, 8.3 to 16.2), and had lower glycated hemoglobin levels (difference, -0.31 percentage points; 95% CI, -0.50 to -0.12). Little time was spent in a hypoglycemic state. No unanticipated safety problems associated with the use of closed-loop therapy during pregnancy occurred (6 instances of severe hypoglycemia, vs. 5 in the standard-care group; 1 instance of diabetic ketoacidosis in each group; and 12 device-related adverse events in the closed-loop group, 7 related to closed-loop therapy). CONCLUSIONS: Hybrid closed-loop therapy significantly improved maternal glycemic control during pregnancy complicated by type 1 diabetes. (Funded by the Efficacy and Mechanism Evaluation Program; AiDAPT ISRCTN Registry number, ISRCTN56898625.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only one AID system is approved for use during pregnancy, and it has been shown to improve time in the target glucose range of 3•5-7•8 mmol/L without increasing the risk of hypoglycaemia.104”
From The future of type 1 diabetes therapy (2025) · cites this paper as [104]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Improvements have been especially notable in vulnerable populations, such as young children 103 and pregnant women with type 1 diabetes.104”
From The future of type 1 diabetes therapy (2025) · cites this paper as [104]
In the citing paper
“The secondary outcomes were also met, with less time spent above range (>140 mg/dL) in the AID group, greater overnight time in target range, and lower A1C (236).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [236]
In the citing paper
“Recent data have shown the clinical benefits and safety of AID use, even though only one study used an AID system with a pregnancyspecific glycemic target.”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [236]
In the citing paper
“The primary outcome of time spent in the pregnancy-specific target range of 63-140 mg/dL was found to be 10.5% higher in the AID group versus standard care (P < 0.001).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [236]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationFeig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
Self-citationEvers, I. M., de Valk, H. W., & Visser, G. H. A. (2004) · BMJ · doi:10.1136/bmj.38043.583160.ee · Cited by 775
Per-Protocol Analyses of Pragmatic Trials
Hernán, M. A., & Robins, J. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmsm1605385 · Cited by 660
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationMurphy, H. R., Howgate, C., O'Keefe, J., Myers, J., Morgan, M., Coleman, M. A., Jolly, M., Valabhji, J., Scott, E. M., Knighton, P., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30406-x · Cited by 346
Self-citationClosed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes
Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602494 · Cited by 279
Self-citationRandomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
Ware, J., Allen, J. M., Boughton, C. K., Wilinska, M. E., Hartnell, S., Thankamony, A., de Beaufort, C., Schierloh, U., Fröhlich-Reiterer, E., Mader, J. K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111673 · Cited by 222
Self-citationTrial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes
Wadwa, R. P., Reed, Z. W., Buckingham, B. A., DeBoer, M. D., Ekhlaspour, L., Forlenza, G. P., Schoelwer, M., Lum, J., Kollman, C., Beck, R. W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210834 · Cited by 191
Self-citationStewart, Z. A., Wilinska, M. E., Hartnell, S., O’Neil, L. K., Rayman, G., Scott, E. M., Barnard, K., Farrington, C., Hovorka, R., & Murphy, H. R. (2018) · Diabetes Care · doi:10.2337/dc17-2534 · Cited by 168
Self-citationEvers, I. M., ter Braak, E. W. M. T., de Valk, H. W., van der Schoot, B., Janssen, N., & Visser, G. H. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.554 · Cited by 152
Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters
Murphy, H. R. (2019) · Diabetologia · doi:10.1007/s00125-019-4904-3 · Cited by 147
Self-citationPathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy
Murphy, H. R., Elleri, D., Allen, J. M., Harris, J. R., Simmons, D. S., Rayman, G. A., Temple, R., Umpleby, A. M., Dunger, D. B., Haidar, A., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2363-6 · Cited by 120
Self-citationClosed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203496 · Cited by 117
Self-citationSCOTT, E. M., Murphy, H. R., Kristensen, K. H., Feig, D. S., Kjölhede, K., Englund‐Ögge, L., Berntorp, K. E., & Law, G. R. (2022) · Diabetes Care · doi:10.2337/dc22-0078 · Cited by 104
Self-citationHypoglycaemia during pregnancy in women with Type 1 diabetes
Ringholm, L., Pedersen‐Bjergaard, U., Thorsteinsson, B., Damm, P., & Mathiesen, E. R. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03604.x · Cited by 101
Tundidor, D., Meek, C. L., Yamamoto, J. M., Martínez-Brú, C., Gich, I. J., Feig, D. S., Murphy, H. R., Corcoy, R., On Behalf of the CONCEPTT Collaborative Group, Murphy, H. R., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0073 · Cited by 63
Self-citationMathiesen, E. R., Alibegovic, A. C., Corcoy, R., Dunne, F., Feig, D. S., Hod, M., Jia, T., Kalyanam, B., Kar, S., Kautzky‐Willer, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00307-2 · Cited by 58
Pharmacokinetics of Insulin Aspart in Pregnant Women With Type 1 Diabetes: Every Day Is Different
Goudie, R. J. B., Lunn, D. J., Hovorka, R., & Murphy, H. R. (2014) · Diabetes Care · doi:10.2337/dc13-2535 · Cited by 45
Self-citationO’Malley, G., Özaslan, B., Levy, C. J., CASTORINO, K. N., Desjardins, D., Levister, C. M., MCCRADY-SPITZER, S. K., Church, M. M., Kaur, R. J., Reid, C. L., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0112 · Cited by 40
Lee, T., Collett, C., Man, M., Hammond, M., Shepstone, L., Hartnell, S., Gurnell, E. M., Byrne, C., SCOTT, E. M., Lindsay, R. S., et al. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-022-04543-z · Cited by 29
Self-citationRankin, D., Hart, R. I., Kimbell, B., Barnard-Kelly, K. D., Brackenridge, A., Byrne, C., Collett, C., Dover, A. R., Hartnell, S., Hunt, K. F., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0479 · Cited by 29
Self-citationLawton, J., Rankin, D., Hartnell, S., Lee, T., Dover, A. R., Reynolds, R. M., Hovorka, R., Murphy, H. R., Hart, R. I., & the AiDAPT Collaborative Group (2023) · Diabetic Medicine · doi:10.1111/dme.15072 · Cited by 12
Self-citation
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
Benhalima, K., Beunen, K., Van Wilder, N., Ballaux, D., Vanhaverbeke, G., Taes, Y., Aers, X.-P., Nobels, F., Marlier, J., Lee, D., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00089-5 · Cited by 131
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 168
Molfetta, S. D., Gioia, L. D., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., Strippoli, G. F., Sorice, G. P., Perrini, S., Natalicchio, A., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3842 · Cited by 91
Metadata
- Authors
- Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K., Rankin, D., Lawton, J., Reynolds, R. M., Flanagan, E., Hammond, M., Shepstone, L., Wilinska, M. E., Sibayan, J., Kollman, C., Beck, R., Hovorka, R., & Murphy, H. R.
- Affiliations
- University of East Anglia (GB)
- ORCID
- Lee, Tara T.M.
- Collett, Corinne
- Bergford, Simon
- Hartnell, Sara
- Scott, Eleanor M.
- Lindsay, Robert S.
- Hunt, Katharine F.
- McCance, David R.
- Barnard-Kelly, Katharine
- Rankin, David
- Lawton, Julia
- Reynolds, Rebecca M.
- Hammond, Matthew
- Shepstone, Lee
- Wilinska, Malgorzata E.
- Sibayan, Judy
- Kollman, Craig
- Beck, Roy
- Hovorka, Roman
- Murphy, Helen R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-26
- Volume
- 389
- Issue
- 17
- Pages
- 1566-1578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387357591
- Cited by
- 241
- References
- 23
- Citations by year
- 2026: 61 · 2025: 102 · 2024: 68 · 2023: 9
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (publishedVersion, cc-by)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Efficacy and Mechanism Evaluation Programme (NIHR EME reference 16/35/01)
- Juvenile Diabetes Research Foundation United States of America (#2-RSC-2019-828-M-N, #22-2013-266)
- Diabetes Research and Wellness Foundation (Sutherland-Earl Fellowship (reference SECF/21))
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, pregnancy, artificial pancreas, continuous glucose monitoring, glycemic control, HbA1c, time in range, hyperglycemia, hypoglycemia, maternal safety, gestational diabetes management, severe hypoglycemia, neonatal outcomes, neonatal hypoglycemia
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Pregnancy, Pregnancy in Diabetics, Blood Glucose Self-Monitoring, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.